Abstract 777P
Background
Cervical cancer is ranked the fourth most common female malignancy worldwide. The prognosis with metastatic or recurrent cervical cancer remains poor, the objective response rate (ORR) of different second chemotherapy treatments ranges from 4.5% to 31.0%. Camrelizumab is an immune checkpoint inhibitor, apatinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, albumin-bound paclitaxel (nab-paclitaxel) is a second-line-recommended chemotherapy in advanced cervical cancer. Our study first assessed the activity and safety of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer.
Methods
This single center, open-label, single-arm, prospective study enrolled patients with advanced cervical cancer. Patients received camrelizumab 200 mg, nab-paclitaxel 260mg/m2 every 3 weeks and apatinib 250 mg once per day as second-line therapy. The primary end point was ORR assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS) and safety.
Results
22 patients were enrolled and received treatment. Median age was 52.0 years (range, 32-69 years). Median follow-up was 10.0 months (range, 2.0-17.0 months). ORR was 71% (95% CI, 51.8% to 91.0%), with 5 complete responses. Median PFS was 15.0 months (95% CI,10.6-19.3 months). Median duration of response and median OS were not reached. The side effects of this strategy are controllable. Treatment-related grade 3 or 4 adverse events (AEs) that occurred were neutropenia and thrombocytopenia, and the most common AEs were hematologic adverse events.
Conclusions
Camrelizumab, apatinib and nab-paclitaxel show promising synergistic effects in advanced cervical cancer. This combination strategy significantly increased the ORR in second-line treatment, and the toxicities are tolerated and controllable.
Clinical trial identification
2019-S1071.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.